VXRT - Vaxart, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.10
+0.03 (+0.98%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.07
Open3.08
Bid2.25 x 800
Ask3.69 x 1000
Day's Range3.08 - 3.20
52 Week Range2.76 - 11.88
Volume39,756
Avg. Volume85,919
Market Cap22.138M
Beta0.39
PE Ratio (TTM)N/A
EPS (TTM)-6.87
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2012-11-09
1y Target Est5.00
Trade prices are not sourced from all markets
  • Business Wire21 days ago

    Vaxart Reports Topline Results from Phase 2 Trial of Teslexivir™ for the Treatment of Condyloma

    Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today reported the topline results from a Phase 2 clinical trial evaluating the safety and efficacy of an antiviral teslexivir 5% gel dosed topically twice daily in 218 subjects for the treatment of condyloma, or anogenital warts. The primary efficacy endpoint was defined as complete clearance of baseline condyloma by week 16.

  • Business Wire24 days ago

    Vaxart to Present at the Jefferies 2018 Global Healthcare Conference

    Vaxart, Inc. (VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Wouter Latour, M.D., president and chief executive officer of Vaxart, will present a company overview at the Jefferies 2018 Global Healthcare Conference on Friday, June 8, 2018, at 1:00 p.m. EST in New York. A live webcast of the presentation will be available by visiting the Investors section of Vaxart’s website at investors.vaxart.com. A replay of the webcast will be archived on Vaxart’s website for 30 days following the presentation.

  • Business Wire24 days ago

    Vaxart to Present at ASM Microbe 2018

    Vaxart, Inc. (VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Roberto Mateo, Ph.D., lead scientist of Vaxart, will present data on the Phase 1 norovirus vaccine trial in a poster presentation at the American Society of Microbiology 2018, taking place from June 7-11, 2018 in Atlanta, Georgia.

  • Was Vaxart Inc’s (NASDAQ:VXRT) Earnings Growth Better Than The Industry’s?
    Simply Wall St.24 days ago

    Was Vaxart Inc’s (NASDAQ:VXRT) Earnings Growth Better Than The Industry’s?

    Measuring Vaxart Inc’s (NASDAQ:VXRT) track record of past performance is a valuable exercise for investors. It allows us to understand whether or not the company has met or exceed expectations,Read More...

  • Business Wirelast month

    Vaxart Announces First Quarter 2018 Financial Results and Corporate Update

    Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the first quarter ended March 31, 2018 and provided a corporate update.

  • Business Wire2 months ago

    Vaxart Appoints Dr. David Taylor as Chief Medical Officer

    Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the appointment of David Taylor, M.D., as Chief Medical Officer.

  • Business Wire2 months ago

    Vaxart Announces $5 Million Inavir® Revenue Milestone

    Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today that it received notification from Daiichi Sankyo Co., Ltd, that sales of Inavir®, a single dose product licensed in Japan to prevent or treat influenza infection, exceeded ¥20 billion in the fiscal year 2017, triggering a $5 million milestone ...

  • Business Wire2 months ago

    Vaxart Appoints Brant Biehn as Senior Vice President, Commercial Operations

    Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the appointment of Brant Biehn as Senior Vice President, Commercial Operations.

  • Business Wire2 months ago

    Vaxart to Present at Two Upcoming Medical Meetings

    Vaxart, Inc. , a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that new preclinical data on its intranasal Chikungunya virus study will be highlighted in an oral presentation at the 28th European Congress of Clinical Microbiology and Infectious Diseases , taking place from April 21-24, 2018 in Madrid, ...

  • Business Wire3 months ago

    Vaxart Announces Oral Presentation of Clinical Data from Oral Influenza Vaccine Program at the World Vaccine Congress

    Vaxart, Inc. , a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, today announced that the complete clinical dataset from the Phase 2 Challenge Study of its H1 influenza oral tablet vaccine will be highlighted in an oral presentation at the World Vaccine Congress , taking place from April 2-5, 2018 in Washington, D.C.

  • Who Really Owns Vaxart Inc (NASDAQ:VXRT)?
    Simply Wall St.3 months ago

    Who Really Owns Vaxart Inc (NASDAQ:VXRT)?

    Today, I will be analyzing Vaxart Inc’s (NASDAQ:VXRT) recent ownership structure, an important but not-so-popular subject among individual investors. Ownership structure of a company has been found to affect shareRead More...

  • Business Wire3 months ago

    Vaxart to Present at the 17th Annual Needham Healthcare Conference

    Vaxart, Inc. , a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, today announced that Wouter Latour, M.D., president and chief executive officer of Vaxart, will present a company overview at the 17th Annual Needham Healthcare Conference on Wednesday, March 28, 2018, at 3:30 p.m.

  • Business Wire4 months ago

    Vaxart Expands Intellectual Property Portfolio With U.S. Patent Allowance

    Vaxart, Inc. a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, today announced that the United States Patent and Trademark Office has issued a notice of allowance for claims related to the Company’s novel manufacturing process for producing hydrazine, a key intermediate in the preparation of teslexivir .

  • Business Wire4 months ago

    Vaxart to Present Clinical Data From Oral Norovirus Vaccine Program at International Congress on Infectious Diseases

    Vaxart, Inc. , a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it will present clinical data from two Phase 1 studies of its norovirus oral tablet vaccine at the upcoming 18th International Congress on Infectious Diseases , taking place from March 1-4, 2018 in Buenos Aires, Argentina.